Antiangiogenic treatment with endostatin results in uncoupling of blood flow and glucose metabolism in human tumors

N. A. Mullani, R. S. Herbst, J. L. Abbruzzese, C. Charnsangavej, E. Kim, H. T. Tran, B. Barron, L. Lamki, K. L. Gould

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Endostatin is a novel antiangiogenic agent currently in phase I trials. In the context of this trial, we are evaluating the use of non-invasive imaging with PET to determine the relationship between tumor blood flow and glucose metabolism in imaged tumors from treated patients. Ten patients have been treated with escalating daily iv Endostatin doses of 30 to 180 mg/m2. PET images were obtained before the start of therapy and again after 28 days of treatment. Each patient was scanned with Oxygen-15 labeled water for estimation of tumor blood flow and Flourine-18 labeled FDG to estimate tumor metabolic activity. In most cases, two distinct tumor-bearing sites were analyzed in each patient. Thus, a total of 19 tumors were imaged. Regional blood flow and standard uptake values (SUV) were computed at baseline and 28 days post treatment and the percentage change in blood flow and SUV plotted as a function of Endostatin dose. Both blood flow and glucose metabolism in the imaged tumors were observed to increase in patients treated with ≤60 mg/m2/d, but became uncoupled in the tumors imaged from patients treated at the 180 mg/m2/d dose level. Thus, in patients receiving Endostatin at a dose of 180 mg/m2/d, blood flow decreased but glucose metabolism increased. This relationship is displayed in Figure 1 below.

Original languageEnglish
Pages (from-to)151
Number of pages1
JournalClinical Positron Imaging (Netherlands)
Volume3
Issue number4
DOIs
Publication statusPublished - 2000

Fingerprint

Endostatins
Blood Glucose
Neoplasms
Therapeutics
Angiogenesis Inhibitors
Regional Blood Flow
Oxygen
Glucose
Water

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Antiangiogenic treatment with endostatin results in uncoupling of blood flow and glucose metabolism in human tumors. / Mullani, N. A.; Herbst, R. S.; Abbruzzese, J. L.; Charnsangavej, C.; Kim, E.; Tran, H. T.; Barron, B.; Lamki, L.; Gould, K. L.

In: Clinical Positron Imaging (Netherlands), Vol. 3, No. 4, 2000, p. 151.

Research output: Contribution to journalArticle

Mullani, N. A. ; Herbst, R. S. ; Abbruzzese, J. L. ; Charnsangavej, C. ; Kim, E. ; Tran, H. T. ; Barron, B. ; Lamki, L. ; Gould, K. L. / Antiangiogenic treatment with endostatin results in uncoupling of blood flow and glucose metabolism in human tumors. In: Clinical Positron Imaging (Netherlands). 2000 ; Vol. 3, No. 4. pp. 151.
@article{a729ddbb356c45be960415e904f4e30d,
title = "Antiangiogenic treatment with endostatin results in uncoupling of blood flow and glucose metabolism in human tumors",
abstract = "Endostatin is a novel antiangiogenic agent currently in phase I trials. In the context of this trial, we are evaluating the use of non-invasive imaging with PET to determine the relationship between tumor blood flow and glucose metabolism in imaged tumors from treated patients. Ten patients have been treated with escalating daily iv Endostatin doses of 30 to 180 mg/m2. PET images were obtained before the start of therapy and again after 28 days of treatment. Each patient was scanned with Oxygen-15 labeled water for estimation of tumor blood flow and Flourine-18 labeled FDG to estimate tumor metabolic activity. In most cases, two distinct tumor-bearing sites were analyzed in each patient. Thus, a total of 19 tumors were imaged. Regional blood flow and standard uptake values (SUV) were computed at baseline and 28 days post treatment and the percentage change in blood flow and SUV plotted as a function of Endostatin dose. Both blood flow and glucose metabolism in the imaged tumors were observed to increase in patients treated with ≤60 mg/m2/d, but became uncoupled in the tumors imaged from patients treated at the 180 mg/m2/d dose level. Thus, in patients receiving Endostatin at a dose of 180 mg/m2/d, blood flow decreased but glucose metabolism increased. This relationship is displayed in Figure 1 below.",
author = "Mullani, {N. A.} and Herbst, {R. S.} and Abbruzzese, {J. L.} and C. Charnsangavej and E. Kim and Tran, {H. T.} and B. Barron and L. Lamki and Gould, {K. L.}",
year = "2000",
doi = "10.1016/S1095-0397(00)00063-7",
language = "English",
volume = "3",
pages = "151",
journal = "Molecular Imaging and Biology",
issn = "1536-1632",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Antiangiogenic treatment with endostatin results in uncoupling of blood flow and glucose metabolism in human tumors

AU - Mullani, N. A.

AU - Herbst, R. S.

AU - Abbruzzese, J. L.

AU - Charnsangavej, C.

AU - Kim, E.

AU - Tran, H. T.

AU - Barron, B.

AU - Lamki, L.

AU - Gould, K. L.

PY - 2000

Y1 - 2000

N2 - Endostatin is a novel antiangiogenic agent currently in phase I trials. In the context of this trial, we are evaluating the use of non-invasive imaging with PET to determine the relationship between tumor blood flow and glucose metabolism in imaged tumors from treated patients. Ten patients have been treated with escalating daily iv Endostatin doses of 30 to 180 mg/m2. PET images were obtained before the start of therapy and again after 28 days of treatment. Each patient was scanned with Oxygen-15 labeled water for estimation of tumor blood flow and Flourine-18 labeled FDG to estimate tumor metabolic activity. In most cases, two distinct tumor-bearing sites were analyzed in each patient. Thus, a total of 19 tumors were imaged. Regional blood flow and standard uptake values (SUV) were computed at baseline and 28 days post treatment and the percentage change in blood flow and SUV plotted as a function of Endostatin dose. Both blood flow and glucose metabolism in the imaged tumors were observed to increase in patients treated with ≤60 mg/m2/d, but became uncoupled in the tumors imaged from patients treated at the 180 mg/m2/d dose level. Thus, in patients receiving Endostatin at a dose of 180 mg/m2/d, blood flow decreased but glucose metabolism increased. This relationship is displayed in Figure 1 below.

AB - Endostatin is a novel antiangiogenic agent currently in phase I trials. In the context of this trial, we are evaluating the use of non-invasive imaging with PET to determine the relationship between tumor blood flow and glucose metabolism in imaged tumors from treated patients. Ten patients have been treated with escalating daily iv Endostatin doses of 30 to 180 mg/m2. PET images were obtained before the start of therapy and again after 28 days of treatment. Each patient was scanned with Oxygen-15 labeled water for estimation of tumor blood flow and Flourine-18 labeled FDG to estimate tumor metabolic activity. In most cases, two distinct tumor-bearing sites were analyzed in each patient. Thus, a total of 19 tumors were imaged. Regional blood flow and standard uptake values (SUV) were computed at baseline and 28 days post treatment and the percentage change in blood flow and SUV plotted as a function of Endostatin dose. Both blood flow and glucose metabolism in the imaged tumors were observed to increase in patients treated with ≤60 mg/m2/d, but became uncoupled in the tumors imaged from patients treated at the 180 mg/m2/d dose level. Thus, in patients receiving Endostatin at a dose of 180 mg/m2/d, blood flow decreased but glucose metabolism increased. This relationship is displayed in Figure 1 below.

UR - http://www.scopus.com/inward/record.url?scp=0000392781&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0000392781&partnerID=8YFLogxK

U2 - 10.1016/S1095-0397(00)00063-7

DO - 10.1016/S1095-0397(00)00063-7

M3 - Article

AN - SCOPUS:0000392781

VL - 3

SP - 151

JO - Molecular Imaging and Biology

JF - Molecular Imaging and Biology

SN - 1536-1632

IS - 4

ER -